Your browser doesn't support javascript.
Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
Jiménez-Alcaide, Estíbaliz; García-Fuentes, Clara; Hernández, Virginia; De la Peña, Enrique; Pérez-Fernández, Elia; Castro, Alejandro; Caballero-Perea, Begoña; Guijarro, Ana; Llorente, Carlos.
  • Jiménez-Alcaide E; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
  • García-Fuentes C; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
  • Hernández V; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
  • De la Peña E; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
  • Pérez-Fernández E; Research Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
  • Castro A; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
  • Caballero-Perea B; Department of Radiation Oncology, Hospital Universitario de Fuenlabrada, Madrid, Spain.
  • Guijarro A; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
  • Llorente C; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
Prostate ; 81(16): 1349-1354, 2021 12.
Article in English | MEDLINE | ID: covidwho-1404607
ABSTRACT

BACKGROUND:

The TMPRSS2 protein has been involved in severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2). The production is regulated by the androgen receptor (AR). It is speculated that androgen deprivation therapy (ADT) may protect patients affected by prostate cancer (PC) from SARS-CoV-2 infection.

METHODS:

This is a retrospective study of patients treated for COVID-19 in our institution who had a previous diagnosis of PC. We analyzed the influence of exposure of ADT on the presence of severe course of COVID-19.

RESULTS:

A total of 2280 patients were treated in our center for COVID-19 with a worse course of disease in males (higher rates of hospitalization, intense care unit [ICU] admission, and death). Out of 1349 subjects registered in our PC database, 156 were on ADT and 1193 were not. Out of those, 61 (4.52%) PC patients suffered from COVID-19, 11 (18.0%) belonged to the ADT group, and 50 (82.0%) to the non-ADT group. Regarding the influence of ADT on the course of the disease, statistically significant differences were found neither in the death rate (27.3% vs. 34%; p = 0.481), nor in the presence of severe COVID-19 need for intubation or ICU admission (0% vs. 6.3%; p = 0.561) and need for corticoid treatment, interferon beta, or tocilizumab (60% vs. 34.7%; p = 0.128). Multivariate analysis adjusted for clinically relevant comorbidities did not find that ADT was a protective factor for worse clinical evolution (risk ratio [RR] 1.08; 95% confidence interval [CI], 0.64-1.83; p = 0.77) or death (RR, 0.67; 95% CI, 0.26-1.74; p = 0.41).

CONCLUSIONS:

Our study confirms that COVID-19 is more severe in men. However, the use of ADT in patients with PC was not shown to prevent the risk of severe COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Prostatic Neoplasms / Severity of Illness Index / SARS-CoV-2 / COVID-19 / Androgen Antagonists Type of study: Etiology study / Observational study / Prognostic study Limits: Aged / Humans / Male / Middle aged Language: English Journal: Prostate Year: 2021 Document Type: Article Affiliation country: Pros.24232

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Prostatic Neoplasms / Severity of Illness Index / SARS-CoV-2 / COVID-19 / Androgen Antagonists Type of study: Etiology study / Observational study / Prognostic study Limits: Aged / Humans / Male / Middle aged Language: English Journal: Prostate Year: 2021 Document Type: Article Affiliation country: Pros.24232